StemCells Begins Phase I/II Trial In Dry Age-Related Macular Degeneration

RELATED NEWS

StemCells Q4 Loss Narrows - Quick Facts

Trade STEM now with

6/21/2012 9:20 AM ET

StemCells, Inc. (STEM: Quote) on Thursday announced the initiation of a Phase I/II clinical trial of the company's proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration or AMD referred to as Geographic Atrophy.

Dry AMD is the most common form of macular degeneration. There are no approved treatments for the condition.

The trial is being conducted at the Retina Foundation of the Southwest's Anderson Vision Research Center in Dallas, Texas.

Click here to receive FREE breaking news email alerts for StemCells Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 133 Articles Next>>

Editors Pick

Gap Profit Climbs 43%

Gap Inc. Thursday after the markets closed that its first quarter profit rose 43% from last year, helped by higher sales and improved margins. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company eaffirmed its fiscal year 2013 earnings outlook, which is below analysts' current consensus estimate.

Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary

After moving sharply lower at the start of trading on Thursday, stocks showed a substantial recovery attempt over the course of the trading day. The rebound came as upbeat housing data helped offset worries about the Federal Reserve. The major averages climbed well off their worst levels of the day but still ended the session in the red.

Obama Outlines Counterterrorism Policy To Confront Shifting Threats

President Barack Obama delivered a highly-anticipated speech on his administration's evolving counterterrorism policies on Thursday, suggesting that the U.S. needs to move away from a "boundless global war on terror." More than a decade after the 9/11 attacks, Obama argued that the terrorist threat has shifted and evolved.